LongBio Pharma Takes a Major Step by Listing on Hong Kong Stock Exchange

In a significant move within China's healthcare sector, LongBio Pharma has successfully listed on the Hong Kong Stock Exchange (HKEX) on June 5, 2026. This milestone marks yet another achievement for Qiming Venture Partners, which has backed seven Initial Public Offerings (IPOs) this year. With its shares initially priced at HK$96.06 and opening at HK$144.30, LongBio enjoys a market capitalization of HK$10.7 billion, solidifying its status as a key player in the biotech industry.

Background on LongBio Pharma

Founded in 2020, LongBio Pharma has established itself as a front-runner in the development of innovative drugs targeting allergic and autoimmune diseases. The company's focus lies in both in-house discovery and cutting-edge clinical development, showcasing a commitment to addressing significant medical needs in China's healthcare landscape.

Leading the company are notable figures such as Dr. Sun Naichao and Dr. Liu Heng. Dr. Sun, a co-founder, is recognized for his critical role in developing omalizumab, the first anti-IgE antibody. His expertise in allergic disease spans several decades, making him a pivotal figure in this domain. On the other hand, Dr. Liu, who serves as Chairman and CEO, brings over 15 years of experience in biopharmaceutical R&D and commercialization, lending invaluable leadership as LongBio navigates the complexities of bringing new treatments to market.

Innovative Drug Pipeline

LongBio Pharma boasts a diverse pipeline of biologic treatments aimed at various conditions, including rhinology, dermatology, respiratory illnesses, hematology, and nephrology. Among its flagship products, LP-003 stands out as an advanced anti-IgE antibody that works by blocking free IgE in the bloodstream and tissues. Early results indicate that LP-003 outperforms omalizumab in treating chronic spontaneous urticaria (CSU), highlighting its potential effectiveness in managing allergic reactions.

Another promising product is LP-005, a unique bispecific complement antibody-fusion protein that targets both C5 and C3b in the complement system. This innovation positions it at the forefront of potential therapies, competing favorably against standard single-target complement inhibitors.

Investment Insights

The investment journey of LongBio Pharma showcases the vision of Qiming Venture Partners. Their lead investment during LongBio's B2 financing round and subsequent contribution in the C round emphasizes Qiming’s confidence in LongBio's capabilities and the growing market for innovative solutions in treating allergic diseases. The firm holds a significant stake of 4.27% in LongBio, underlining its commitment to supporting the company through its growth phases.

With the rising prevalence of allergic conditions such as asthma and allergic rhinitis in China, LongBio is poised to seize considerable market opportunities. The listing on HKEX not only marks a transition from laboratory research to commercial viability but also reinforces LongBio's potential to be a leader in allergy treatment in China.

Dr. Kan Chen, a partner at Qiming Venture Partners, spoke to the importance of this pioneering step for LongBio. He emphasized, "The listing of LongBio Pharma represents a crucial milestone in the company’s journey from research to market access, and it reflects Qiming’s agility in recognizing and investing in future-altering healthcare innovations. We remain focused on addressing unfulfilled clinical needs and will continue pursuing groundbreaking medical technologies with competitive advantages on a global scale."

Conclusion

As LongBio Pharma embarks on this new chapter after its successful IPO, the anticipation surrounding its innovative therapies is palpable. The firm’s robust pipeline and strong foundational leadership position it to transform the treatment landscape for allergic and autoimmune diseases, not just in China but potentially worldwide. LongBio’s journey exemplifies the thriving potential within the biotechnology sector and highlights the growing emphasis on innovative medical solutions to enhance patient care.